CO-WESTERN-UNION
12.9.2020 06:52:14 CEST | Business Wire | Press release
Western Union , a global leader in cross-border, cross-currency money movement and payments, and the Western Union Foundation have announced the Foundation’s pledge of USD 250K in relief to support the immediate and long term recovery needs of refugees including the people displaced from Greece’s Moria Camp. More than 12,000 people have been evacuated from the Moria Camp on the island of Lesbos, which was destroyed by fires earlier this week.
The camp was the temporary home to migrants, refugees and asylum seekers from more than 70 different countries , among them elderly, pregnant women, children, and people with disabilities. With a fire devastating their only place of refuge, thousands are now without shelter and access to water and sanitation.
The Foundation will deploy USD 100K to support the International Rescue Committee (IRC) in their immediate relief efforts for the Moria camp evacuees. Funds will support secure accommodations, mental health and psychosocial support, and distribution of urgent supplies, with a focus on safety to avoid the risk of COVID-19 transmission. An additional USD 150K in funding will support longer-term advocacy and relief efforts to enable sustainable living for refugees in Greece.
“Western Union and our Foundation are unrelenting in our support of migrants, refugees and forcibly displaced people around the globe. Our hearts are with the people of the Moria camp,” said Hikmet Ersek, Western Union President and CEO. “Many of our customers are migrants who have moved from their home to their host country for a variety of reasons - economic, financial, family-driven, or security reasons.”
“We call on global leaders to come together to support this vulnerable community as their survival is at stake. We know first-hand that people thrive when they are given fundamental support and opportunities through education, job skills training, and access to the global economy.”
In a recent statement released by the IRC, Dimitra Kalogeropoulou, IRC Greece Country Director, said, “The recent events in Moria are unthinkable but, tragically, predictable. The dire situation on the islands has gone on for far too long. With the camp destroyed and residents evacuated, the situation is alarming as there is no secure place to live. These already traumatized people have now lost what few belongings they had; they have nothing.”
Since its inception, the Western Union Foundation has granted USD 10.5M globally to support displaced persons, including immigrants, refugees, asylees, conflict-affected, and migrants. This includes USD 2.5M across Europe.
Since 2018, the Western Union Foundation, in partnership with MIT D-Lab, has been providing hands-on, experiential learning in design, innovation, and entrepreneurship for refugees in Greece. These individuals are being equipped with technical and soft skills to establish their own business while building confidence, agency, and problem-solving ability.
Globally, more than 70 million people were forced from home by conflict and persecution at the end of 2018, according to the UN. Among them are nearly 30 million refugees, over half of whom are under the age of 18. There are also millions of stateless people who have been denied a nationality and access to fundamental rights such as education, healthcare, employment, and freedom of movement.
WU-G
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .
About the Western Union Foundation
The Western Union Foundation believes that education is the surest pathway to economic opportunity. After nearly 20 years of impact, we are continuing to deliver against our mission with our Opportunity Beyond Borders commitment, with a focus on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding to communities in crisis through disaster relief and other humanitarian efforts, a key reason for forced migration. To date, more than $126 million granted to fund projects and scholarships in 174 countries across the globe. The Western Union Foundation is a separate charitable corporation that is tax-exempt under 501(c)(3) of the US Internal Revenue Code and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for US income tax purposes. To learn more, visit wu.com/foundation or follow us on Twitter @TheWUFoundation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005525/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
